LYNKUET (Bayer Australia Ltd)
Product name
LYNKUET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
179 (255 working days)
Active ingredients
elinzanetant
Registration type
NCE/ NBE
Indication
The approved indication for this therapeutic good is:
- LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see Section 5.1 Pharmacodynamic properties – Clinical Trials).